3
Indication details
- Combined Agent(s)
- Carboplatin and etoposide
- Control Arm
- Placebo plus carboplatin and etoposide
- Therapeutic Indication
- First-line treatment of extensive-stage SCLC
- Tumour Type
-
Thoracic Malignancies
- Tumour Sub-type
- Small-cell Lung Cancer
- Tumour Stage
- Extensive-stage
- Trial Name
- IMpower133
- NCT Number
- NCT02763579
- Trial Phase
- Phase III
Approval details
- FDA Approval
- FDA approval March 2019
- EMA Approval
- EMA (CHMP) July 2019 EC decision September 2019
Primary Outcome(s)
- Primary Outcome(s)
- PFS/OS
- Evaluated Outcome
- OS
- Form(s)
- Form 2a
Outcome Data
- PFS Control
- 4.3 months
- PFS Gain
- 0.9 months
- PFS HR
- 0.77 (0.63-0.95)
- OS Control
- 10.3 months
- OS Gain
- 2.0 months
- OS HR
- 0.76 (0.60-0.95)
Adjustments
- QoL Comment
-
Benefit for delayed deterioration in global QoL not significant
Score (after adjustments)
- Preliminary non-curative score
-
3
- Non-curative score
-
3
Scorecard details
- ESMO-MCBS version
- ESMO-MCBS v1.1
- Scorecard ID
- 194
- Scorecard version
- 1
- Issue date
- 17.07.2020
- Last update
- 18.09.2023
Legend
Information about symbols, abbrevations and color codes
Red = negative
Green = positive
Grey = neutral
?
Grey + ? = neutral with pending data
- DFS
- Disease-Free Survival
- DoR
- Duration of Response
- EFS
- Event-Free Survival
- HR
- Hazard Ratio
- NEB
- No evaluable benefit
- NI
- Non-inferiority Study
- ORR
- Overall Response Rate
- OS
- Overall Surival
- pCR
- Pathological Complete Response/Remission
- PFS
- Progression-Free Survival
- QoL
- Quality of Life
- RFS
- Relapse-Free Survival
- RR
- Response Rate
QoL adjustments
Other adjustments*
Serious and disabling adverse effects
Red = negative / deterioration
Green = positive / improvement
QoL adjustments
Red = negative / deterioration
Green = positive / improvement
Other adjustments*
Red = negative / deterioration
Green = positive / improvement
Serious and disabling adverse effects
Red = negative / deterioration
Green = positive / improvement
* Other adjustments include:
- Long-term plateau in the survival curve
- Long-term plateau in the PFS curve
- Early stopping or crossover
- Only improved PFS mature data shows no OS advantage and no improved Qol.